| abstract |
The present invention provides nanoparticles coated with fusion proteins, comprising a domain that binds to a cancer marker and a domain comprising a toxic polypeptide. In some embodiments, the targeted cancer marker is the urokinase plasminogen activator (uPAR) receptor, insulin-like growth factor 1 (IGF1R) receptor, EGFR, HER2, and / or another member of the ErbB receptor family. In some embodiments, the molecule that binds to a cancer marker is an amino terminal moiety of uPA or a variant capable of binding to uPAR and / or IGF1 or a variant capable of binding to IGF1R. In some embodiments, the toxic polypeptide is a bacterial exotoxin. |